Serum matrix metalloproteinases-3 levels in @entity1 with XXXX .

@entity1 @entity7126 @entity5 @entity1549 @entity1691
Cumulated evidence indicates that @entity1549 ( @entity1549 ) is significantly involved in @entity5 progression. Recent studies yielded conflicting results regarding the association between serum @entity1549 and @entity1691 ( @entity1691 ). To clarify this correlation, we performed a meta-analysis. Potential relevant studies were identified by searching the following databases: PubMed, Embase, CINAHL, Science Citation Index database, the Cochrane Library, Current Contents Index, Chinese Biomedical, the Chinese Journal Full-Text, and the Weipu Journal. Data from eligible studies were extracted and included into the meta-analysis using a random-effect model. Standardized mean differences (SMDs) and 95% confidence intervals (CIs) were used to assess the association between serum @entity1549 levels and @entity1691 . Thirteen case-control studies, including 707 @entity1691 cases and 442 healthy controls, were selected for the meta-analysis. The results indicate a significantly higher serum @entity1549 level in @entity1 with @entity1691 than that in the controls (cases vs controls: @entity7126 = 1.31, 95%CI = 0.84-1.78, P < 0.001). Ethnicity-subgroup analysis indicated a higher @entity1549 level in Asian and Caucasian @entity1 with @entity1691 (all P < 0.05). This meta-analysis indicates that increased serum @entity1549 level correlates with the development of @entity1691 , suggesting that @entity1549 may present a clinical value in reflecting the progression of @entity1691 . Further larger sample size studies are warranted.
